We realize that most biotechs face a continual struggle for cash flow in the worst business climate in 60 years. We can help you act quickly and decisively to address critical short-term challenges created by the credit crisis, such as cash forecasting, liquidity, working capital and identifying funding sources. We can help you manage cost reduction and credit exposures. Our solutions will increase your capability to seize market opportunities and to not only gain but to sustain competitive advantages over time.